Comparison of Vibrating Mesh and Jet Nebulizers During Noninvasive Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Авдеев, С. Н.; Нуралиева, Г. С.; Soe, Aung Kyaw; Гайнитдинова, В. В.; Fink, James B.

doi:10.1089/jamp.2020.1665

Cited by 6 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four studies 23 , 24 , 26 , 29 reported the results of FVC, the test for heterogeneity resulted in an I2=0.0%, P=0.474, and using a fixed-effects model, the results showed an MD (0.11 [95% CI, −0.18 to 0.41], P=0.459), which showed no statistically significant difference. ( Figure 8 ) It suggested that there was also no difference between VMN and JN in improving lung capacity.…”

Section: Resultsmentioning

confidence: 99%

“…Initially, 172 related literatures were retrieved and screened according to the inclusion and exclusion criteria after reading the titles and abstracts of the literatures, and finally 10 qualified clinical studies were included, [23][24][25][26][27][28][29][30][31][32] with a total of 314 study subjects, including 157 subjects in the VMN group and 157 subjects in the JN group. The screening process is shown in Figure 1, Reason of exclusion after full-text reading is shown in Supplementary material Data S2, and the basic characteristics of the included studies are shown in Table 1.…”

Section: Study Retrieved and Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Application of Vibrating Mesh Nebulizer and Jet Nebulizer in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta‐analysis

Feng,

Han,

Wang

et al. 2024

COPD

View full text Add to dashboard Cite

Objective To comparison of the application of Vibrating Mesh Nebulizer and Jet Nebulizer in chronic obstructive pulmonary disease (COPD). Research Methods This systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statements. The primary outcome measures analyzed included: The amount of inhaler in the urine sample at 30 minutes after inhalation therapy (USAL0.5), The total amount of inhaler in urine sample within 24 hours (USAL24), Aerosol emitted, Forced expiratory volume in 1 second (FEV 1 ), Forced vital capacity (FVC). Results Ten studies were included with a total of 314 study participants, including 157 subjects in the VMN group and 157 subjects in the JN group. The data analysis results of USAL0.5, MD (1.88 [95% CI, 0.95 to 2.81], P = 0.000), showed a statistically significant difference. USAL24, MD (1.61 [95% CI, 1.14 to 2.09], P = 0.000), showed a statistically significant difference. The results of aerosol emitted showed a statistically significant difference in MD (3.44 [95% CI, 2.84 to 4.04], P = 0.000). The results of FEV 1 showed MD (0.05 [95% CI, −0.24 to 0.35], P=0.716), the results were not statistically significant. The results of FVC showed MD (0.11 [95% CI, −0.18 to 0.41], P=0.459), the results were not statistically significant. It suggests that VMN is better than JN and provides higher aerosols, but there is no difference in improving lung function between them. Conclusion VMN is significantly better than JN in terms of drug delivery and utilization in the treatment of patients with COPD. However, in the future use of nebulizers, it is important to select a matching nebulizer based on a combination of factors such as mechanism of action of the nebulizer, disease type and comorbidities, ventilation strategies and modes, drug formulations, as well as cost-effectiveness, in order to achieve the ideal treatment of COPD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Study Retrieved and Characteristicsmentioning

confidence: 99%

Comparison of the Application of Vibrating Mesh Nebulizer and Jet Nebulizer in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta‐analysis

Feng,

Han,

Wang

et al. 2024

COPD

View full text Add to dashboard Cite

show abstract

“…We here show that NTB‐NS can be aerosolized with a vibrating mesh nebulizer without perturbing the physicochemical properties that enable enhanced lung pharmacokinetics. Of note, vibrating mesh nebulizers have been shown in clinical studies to provide superior lung deposition or therapeutic outcomes compared to jet nebulizers which have a longer history of clinical use 54–56 . Importantly, NTB‐NS can be lyophilized for long‐term storage and remote shipping.…”

Section: Resultsmentioning

confidence: 99%

“…Of note, vibrating mesh nebulizers have been shown in clinical studies to provide superior lung deposition or therapeutic outcomes compared to jet nebulizers which have a longer history of clinical use. [54][55][56] Importantly, NTB-NS can be lyophilized for long-term storage and remote shipping. We thus expect the final product to be a lyophilisate powder that patients can rehydrate with a co-packaged medical-grade vehicle solution prior to self-administration via a portable vibrating mesh nebulizer.…”

Section: In Vivo Therapeutic Efficacy Of Locally Administered Ntb-ns ...mentioning

confidence: 99%

Development of nintedanib nanosuspension for inhaled treatment of experimental silicosis

Silva

Vieira

Cabral

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

Silicosis is an irreversible and progressive fibrotic lung disease caused by massive inhalation of crystalline silica dust at workplaces, affecting millions of industrial workers worldwide. A tyrosine kinase inhibitor, nintedanib (NTB), has emerged as a potential silicosis treatment due to its inhibitory effects on key signaling pathways that promote silica‐induced pulmonary fibrosis. However, chronic and frequent use of the oral NTB formulation clinically approved for treating other fibrotic lung diseases often results in significant side effects. To this end, we engineered a nanocrystal‐based suspension formulation of NTB (NTB‐NS) possessing specific physicochemical properties to enhance drug retention in the lung for localized treatment of silicosis via inhalation. Our NTB‐NS formulation was prepared using a wet‐milling procedure in presence of Pluronic F127 to endow the formulation with nonadhesive surface coatings to minimize interactions with therapy‐inactivating delivery barriers in the lung. We found that NTB‐NS, following intratracheal administration, provided robust anti‐fibrotic effects and mechanical lung function recovery in a mouse model of silicosis, whereas a 100‐fold greater oral NTB dose given with a triple dosing frequency failed to do so. Importantly, several key pathological phenotypes were fully normalized by NTB‐NS without displaying notable local or systemic adverse effects. Overall, NTB‐NS may open a new avenue for localized treatment of silicosis and potentially other fibrotic lung diseases.

show abstract

“…In vivo and in vitro studies report greater aerosol delivery using vibrating mesh nebulizers when compared to jet nebulizers (JN) [ 4 , 5 , 6 , 7 , 8 ]. These advantages are related to the physical characteristics of this device, such as low residual volume, no gas flow required to generate the aerosol and minimal disruption of ventilation compared with JNs [ 3 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Does Valved Holding Chamber Improve Aerosol Lung Deposition with a Jet Nebulizer? A Randomized Crossover Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Using valved holding chambers (VHC) during aerosol therapy has been reported to improve the inhaled dose with various aerosol devices, including vibrating mesh nebulizers. The aim of this study was to quantify the pulmonary deposition of a jet nebulizer (JN) with and without a VHC, and a mesh nebulizer (MN) with a VHC in a randomized cross-over trial with seven healthy consenting adults. Our hypothesis was that the use of a VHC would improve deposition with the JN. Diethylnitriaminopentacetic acid with technetium (DTPA-Tc99m), with the activity of 1 mC with 0.9% saline solution was nebulized. The radiolabeled aerosol was detected by 2D planar scintigraphy after administration. The pulmonary deposition was greater with a JN with a VHC (4.5%) than a JN alone (3.2%; p = 0.005. However, an MN with a VHC (30.0%) was six-fold greater than a JN or JN with a VHC (p < 0.001). The extrapulmonary deposition was higher in the JN group without a VHC than in the other two modalities (p < 0.001). Deposition in the device was greater with a JN + VHC than an MN+/VHC (p < 0.001). Lower residual drug at the end of the dose was detected with an MN than either JN configuration. The exhaled dose was greater with a JN alone than either an MN or JN with VHC (p < 0.001). In conclusion, the addition of the VHC did not substantially improve the efficiency of aerosol lung deposition over a JN alone.

show abstract

Comparison of Vibrating Mesh and Jet Nebulizers During Noninvasive Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Cited by 6 publications

References 36 publications

Comparison of the Application of Vibrating Mesh Nebulizer and Jet Nebulizer in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta‐analysis

Comparison of the Application of Vibrating Mesh Nebulizer and Jet Nebulizer in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta‐analysis

Development of nintedanib nanosuspension for inhaled treatment of experimental silicosis

Does Valved Holding Chamber Improve Aerosol Lung Deposition with a Jet Nebulizer? A Randomized Crossover Study

Contact Info

Product

Resources

About